Sanofi (SNY)

45.74
0.18 0.40
NASDAQ : Health Technology
Prev Close 45.56
Open 45.55
Day Low/High 45.48 / 45.84
52 Wk Low/High 40.00 / 47.11
Volume 606.93K
Avg Volume 1.46M
Exchange NASDAQ
Shares Outstanding 2.51B
Market Cap 114.02B
EPS 2.00
P/E Ratio 24.49
Div & Yield 1.16 (2.57%)

Latest News

New England Journal Of Medicine Publishes Data Showing Improved Survival With Jevtana® (cabazitaxel) Over Second Androgen Receptor-targeted Agent In Metastatic Castration-resistant Prostate Cancer

New England Journal Of Medicine Publishes Data Showing Improved Survival With Jevtana® (cabazitaxel) Over Second Androgen Receptor-targeted Agent In Metastatic Castration-resistant Prostate Cancer

- CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.

Sanofi Canada Receives Gold-Level Parity Certification

Sanofi Canada Receives Gold-Level Parity Certification

Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) First global biopharmaceutical company with a presence in Canada to be certified by Women in Governance LAVAL, QC, Sept.

Hagens Berman Files Second Class-Action Lawsuit Regarding Concealed Zantac Cancer Risk

Hagens Berman Files Second Class-Action Lawsuit Regarding Concealed Zantac Cancer Risk

Class-action law firm Hagens Berman has filed a second lawsuit regarding Sanofi and Boehringer Ingelheim's intentionally concealed cancer risks in its popular heartburn medication, Zantac.

Happify Health And Sanofi Sign Global Agreement To Bring Prescription Digital Mental Health Therapeutics To Individuals With Multiple Sclerosis

Happify Health And Sanofi Sign Global Agreement To Bring Prescription Digital Mental Health Therapeutics To Individuals With Multiple Sclerosis

NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (NASDAQ: SNY) to advance the application of digital therapeutics to...

Hagens Berman: National Class-Action Lawsuit Accuses Sanofi Of Concealing Zantac Cancer Risk

Hagens Berman: National Class-Action Lawsuit Accuses Sanofi Of Concealing Zantac Cancer Risk

A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally concealing risks in its popular heartburn medication, Zantac, which has been found to contain a carcinogenic chemical at 26,000 times the FDA-approved limit,...

FDA Says Sanofi's Zantac Medication Has Impurity That Could Cause Cancer

FDA Says Sanofi's Zantac Medication Has Impurity That Could Cause Cancer

The FDA isn't calling for consumers to stop taking heartburn relief medicines with ranitidine 'at this time.'

Sanofi Delivered Solid Growth In Q2 2019

Sanofi Delivered Solid Growth In Q2 2019

PARIS , July 29, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.

Busy Earnings Week, China Trade, Fed Moves, Trading Beyond Meat: Market Recon

Busy Earnings Week, China Trade, Fed Moves, Trading Beyond Meat: Market Recon

The real threat here would be if the Fed were fooled by domestic economic data that remains better than bad, from properly preparing for a very uncertain future.

Alphabet Shares Soar After Excellent Earnings Results

Alphabet Shares Soar After Excellent Earnings Results

A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: SID, SNY Downgrades: EEI, NTP, PLAY Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Sanofi Oncology Pipeline Targeting Various Cancers Highlighted At ASCO 2019

Sanofi Oncology Pipeline Targeting Various Cancers Highlighted At ASCO 2019

- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma

Sanofi Recognized By DiversityInc As A Top 50 Company

Sanofi Recognized By DiversityInc As A Top 50 Company

BRIDGEWATER, N.J.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

A Cereal Titan, a Jewelry Chain and Other Stocks That Look Good Short

SNY, RYN, I, SIG and K all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DHX, EWBC, KE, MSON, OMN, RDWR, RNR, SEE Downgrades: AR, FTAI, K, RYN, SNY, TWO, VNDA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

JPMorgan and Oracle Jump After Warren Buffett Buys Shares

JPMorgan and Oracle Jump After Warren Buffett Buys Shares

Warren Buffett's big buys of Oracle and JPMorgan have those stocks jumping Thursday.

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Nvidia, nvidia, NVIDIA. In non-Nvidia news, the market faces some serious threats in the back half of 2018. And hey, about Elon Musk's latest interview ...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CFBK, CLDT, SNY, VET Downgrades: ADNT, AOI, BVN Initiations: AMMA Read on to get TheStreet Quant Ratings' detailed report:

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

TheStreet Quant Rating: B (Buy)